News in early breast cancer this year was marked by updated U.S. Preventive Services Task Force (USPSTF) screening ...

Novartis (NVS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Steve Scala from ...

Q3 2024 Earnings Call Transcript October 29, 2024 Novartis AG beats earnings expectations. Reported EPS is $2.06, expectations were $1.96. Operator: Good morning and good afternoon, and welcome to the ...

So, overall, we think we now have really the perfect positioning that we would want for Kisqali to succeed in the long run. As a reminder, the early breast cancer indication doubles the number of ...

Reports Q3 revenue $12.82B, consensus $12.76B. Vas Narasimhan, CEO of Novartis (NVS), said: “Novartis delivered another quarter of ...

Novartis reported strong third-quarter sales of $12.823 billion, beating consensus, with key growth drivers contributing to momentum and upgraded guidance for 2024.

Basel: This month, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast cancer were updated to ...

"There is no indication that Tether is under investigation," Tether CEO Paolo Ardoino said on X. A spokesperson for the U.S. attorney's office declined to comment. The Treasury Department has been ...

Cosentyx exceeded my expectations in the second quarter thanks to the strong uptake in the recently approved indication hidradenitis ... I expect Kisqali net sales to grow nearly 40% Y/Y to ...

as well as the recent FDA approval and CHMP positive opinion for Kisqali in the EBC indication. The updated guidelines, consistent with the FDA indication per the NATALEE trial, approximately ...